Fifth Third Wealth Advisors LLC Invests $448,000 in Insulet Corporation $PODD

Fifth Third Wealth Advisors LLC acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,426 shares of the medical instruments supplier’s stock, valued at approximately $448,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Trust Co. of Toledo NA OH acquired a new position in shares of Insulet during the second quarter worth approximately $35,000. Fourpath Capital Management LLC acquired a new position in shares of Insulet during the second quarter worth approximately $225,000. Ramirez Asset Management Inc. boosted its position in shares of Insulet by 50.0% during the second quarter. Ramirez Asset Management Inc. now owns 300 shares of the medical instruments supplier’s stock worth $94,000 after buying an additional 100 shares during the period. IFP Advisors Inc lifted its position in Insulet by 7.4% in the second quarter. IFP Advisors Inc now owns 1,358 shares of the medical instruments supplier’s stock worth $472,000 after purchasing an additional 93 shares during the period. Finally, Callan Family Office LLC acquired a new stake in Insulet in the second quarter worth approximately $375,000.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $314.52 on Monday. The company’s fifty day moving average is $323.75 and its two-hundred day moving average is $300.64. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $226.50 and a 12-month high of $353.50. The company has a market cap of $22.14 billion, a P/E ratio of 95.60, a price-to-earnings-growth ratio of 2.61 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period in the previous year, the business earned $0.55 EPS. The company’s revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PODD. Rothschild & Co Redburn upped their target price on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Truist Financial began coverage on Insulet in a research report on Monday, June 16th. They issued a “buy” rating and a $365.00 target price for the company. Piper Sandler upped their target price on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group upped their target price on Insulet from $353.00 to $399.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $347.67.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.